I. Supplementary Methods

Synthesis and characterization of the lead compound 1 (UMI-59) and its analog 2 (UMI-77)
General: All reactions were performed under anhydrous conditions. Reagents were used as supplied without further purification. Purities of final compounds were assessed by analytical HPLC performed on a Shimadzu system with a Restek Ultra C18 (4.6 × 150 mm, 5mm particle size) column and a gradient of acetonitrile with 0.1 vol% TFA (10-90%) in water with 0.1 vol% TFA. Semipreparative HPLC was performed on a Shimadzu system with a Restek Ultra C18 (21.2 × 150 mm, 5mm particle size) column. NMR spectra were obtained in DMSO-d 6 and results were recorded on a Varian 400 instrument. High resolution mass spectrometry (HRMS) analysis was performed on an Agilent Q-TOF system. Supplementary Scheme 1. Synthetic pathway to prepare 1 (UMI-59) (R = thiophene) and 2 (UMI-77) (R = 4-Bromophenyl).
1 (UMI-59) and 2 (UMI-77) were synthesized as shown in Scheme 1. Commercially available 1-methoxy-4-nitronaphthalene underwent electrophilic aromatic substitution with N-iodosuccinamide (1) to provide the -4-desired aryl iodide 4. Intermediate 4 was coupled with methyl thioglycolate using optimized palladiumcatalyzed conditions (2, 3) . The nitro group of the intermediate was subsequently reduced to amine using iron powder (4) and the amine was reacted with 2-thiophenesulfonyl chloride or 4-bromobenezesulfonyl chloride in presence of pyridine to provide the desired sulfonamide intermediates 6 and 7. The last step involved onepot demethylation/ester hydrolysis using BBr 3 followed by mildly acidic workup. The crudes from the last step were purified by either trituration or reverse phase semipreparative HPLC to afford the final compounds 1 and 2. 1 (UMI-59): 2-((1-Hydroxy-4-(thiophene-2-sulfonamido)naphthalen-2-yl)thio)acetic acid. 
Protein purification
His-tagged proteins containing Mcl-1 (residues 171-327), Bcl-2 (residues 1-202 with inserted Bcl-xL sequence from residues 35 to 50), Bcl-xL (residues 1-209 lacking its C-terminal transmembrane domain with a -5-deletion of the flexible loop region 45 -85), Bcl-w (residues 1-155), A1/Bfl-1 (residues 1-151), were expressed from the pHis-TEV vector (a modified pET vector) in E. coli BL21 (DE3) cells. Cells were grown at 37 ºC in 2xYT containing antibiotics to an OD 600 density of 0.6. Protein expression was induced by 0.4 mM IPTG at 37 ºC for 4 hours. Cells were lysed in 50 mM Tris pH 8.0 buffer containing 500 mM NaCl, 0.1% bME and 40 μl of Leupectin/Aprotin. All protein were purified from the soluble fraction using Ni-NTA resin BID was used at 1 nM. 5 μL of the tested compound in DMSO and 120 μL of protein/probe complex in the assay buffer (100 mM potassium phosphate, pH 7.5; 100 μg/ml bovine gamma globulin; 0.02% sodium azide, purchased from Invitrogen, Life Technologies) were added to assay plates (Microfluor 2Black, Thermo Scientific), incubated at room temperature for 3 h and the polarization values (mP) were measured at an excitation wavelength at 485 nm and an emission wavelength at 530 nm using the plate reader Synergy H1 Hybrid, BioTek. IC 50 values were determined by nonlinear regression fitting of the competition curves (GraphPad Software). 
Surface plasmon resonance (SPR) binding assays
Solution competitive SPR based assay using immobilized Bax protein
-7-Recombinant Bax protein (residues 1-100) purchased from Novus Biologicals, Inc., was immobilized on
Induced fit docking (IFD)
Schrödinger's IFD predicts ligand binding modes and concomitant structural changes in the protein by combining Glide (the docking program of Schrödinger) and the refinement module in Prime (the protein structure prediction program of Schrödinger). Its main application is to generate an accurate complex structure for a ligand known to be active but that cannot be docked in a rigid structure of the receptor. IFD was used in -8-our study because it incorporates the protein flexibility as well as the ligand flexibility, which is important for accurate docking, especially when the protein is too flexible. The protocol that was used for IFD studies is consisted of the following steps: (1) Constrained minimization of the protein with an RMSD cutoff of 0.18 Å. Schrödinger's MC/SD dynamic simulation performs constant temperature calculations that take advantage of the strengths of Monte Carlo methods for quickly introducing large changes in a few degree of freedom, and stochastic dynamics for its effective local sampling of collective motions. The MC/SD dynamic simulation time in our study was set to 100 ps by allowing movement of the docked ligand and the residues which is less than 6 Å to the ligand. The force field used was set to OPLS_2001. Default values were used for all other parameters.
Metabolic Stability Assay
The β-NADPH (Sigma-Aldrich) was dissolved in 0.1 M phosphate buffer containing 3.3 mM MgCl 2 right before use. The pooled mice liver microsomes (XenoTech, LLC) were diluted with 0.1 M phosphate buffer containing 3.3 mM MgCl 2 , followed by adding the reduced β-NADPH solution. After initiating the enzymes by adding β-NADPH, the mixture was incubated at 37 °C for 30 min. The tested compound UMI-77 was added into the mixture and incubated at 37 °C. The final concentrations of the compound, microsomes, β-NADPH, phosphate buffer and MgCl 2 were 1 μM, 1.2 mg/ml, 1 mM, 0.1 M, and 3.3 mM, respectively. An FITC-A --> 
